Home > Oncology > ASCO 2021 > Gynaecological Cancers > Adjuvant chemotherapy does not improve outcome in patients with locally advanced cervical cancer

Adjuvant chemotherapy does not improve outcome in patients with locally advanced cervical cancer

Presented By
Prof. Linda Mileshkin, Peter MacCallum Cancer Center, Australia
Conference
ASCO 2021
Trial
Phase 3, OUTBACK
Results of the randomised, phase 3 OUTBACK trial do not support the use of adjuvant chemotherapy after chemoradiation in women with locally advanced cervical cancer. At 5 years, both overall and progression-free survival were similar in the respective treatment arms. The standard treatment for locally advanced disease is chemoradiation followed by brachytherapy. However, a significant percentage of women still relapse and die from the development of distant metastatic disease [1]. A randomised trial suggested additional benefit of the use of concurrent cisplatin-gemcitabine and radiation followed by 2 cycles of cisplatin-gemcitabine [2]. The randomised, phase 3 OUTBACK trial (ACTRN12610000732088) was designed to determine the effects of adjuvant chemotherapy after chemoradiation on survival. Eligible women (n=919) had locally advanced cervical cancer (FIGO 2008 sta...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on